Reliq Health Technologies - CEO Dr. Lisa Crossley
CEO Dr. Lisa Crossley
Source: Reliq Health Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Reliq Health Technologies (RHT) has signed five new contracts with two home health agencies, two physician practices and a wound care practice
  • The contracts are expected to add at least 10,000 new patients in California, Florida, Nevada and Texas to Reliq’s iUGO Care platform
  • Onboarding of these patients is expected to begin next month
  • Reliq Health Technologies specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring
  • Reliq Health Technologies Inc. (RHT) opened trading at C$0.52 per share

Reliq Health Technologies (RHT) has signed five new contracts with two home health agencies, two physician practices and a wound care practice.

The contracts are expected to add at least 10,000 new patients in California, Florida, Nevada and Texas to Reliq’s iUGO Care platform over the next three quarters.

“We are excited to be expanding in Kentucky, where the state Medicaid program has significantly increased its coverage for remote patient monitoring,” said Dr. Lisa Crossley, CEO at Reliq Health Technologies, Inc.

“There are over 1.2 Million adults covered by Medicaid in the state of Kentucky (Medicaid.gov). According to the Chronic Care Policy Alliance, approximately 22 per cent of the population in Kentucky or roughly 1 Million residents are in Poor to Fair health. The expanded scope of Kentucky’s Medicaid program will allow patients with heart disease, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), diabetes, hypertension, cancer, stroke, mental health issues or who are pregnant to be monitored remotely by their healthcare providers. Over 50 per cent of Kentucky residents live in rural communities. Using Reliq’s iUGO Care solution improves access to care for these patients, improving health outcomes and quality of life.”

“We are also very pleased to be adding four new clients with patients in California, Florida, Nevada and Texas, including a multi-state wound care practice. According to the Wound Care Education Institute (wcei.net), over 15% of Medicare patients are being treated for chronic wounds. Remote monitoring of these patients with iUGO Care allows care providers to track wound healing progress and intervene early as needed to prevent complications that can lead to amputations, sepsis and even death. Altogether these five contracts are expected to add over 10,000 patients to our platform in the next nine months at an average revenue of $65 per patient per month (at 75% gross margin). Onboarding of these patients is expected to begin next month. The Company remains on track to onboard over 100,000 patients by the end of calendar year 2022 and over 200,000 patients by the middle of calendar year 2023.”

Reliq Health Technologies specializes in developing Software-as-a-Service (SaaS) solutions for remote patient monitoring, telemedicine, and care collaboration. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

Reliq Health Technologies Inc. (RHT) opened trading at C$0.52 per share.


More From The Market Herald

" BetterLife (CSE:BETR) files a comprehensive patent for BETR-001 and other LSD derivatives

BetterLife Pharma (BETR) filed a PCT patent application and a U.S. application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD.

" Hemostemix (TSXV:HEM) appoints Dr. Ernst von Schwarz to its Scientific Advisory Board

Hemostemix (HEM) has appointed Dr. Ernst von Schwarz, MD, Ph.D., FESC, FACC, FSCAI to its Scientific Advisory Board.

" Mindset Pharma (CSE:MSET) signs intellectual property license with Cybin (NEO:CYBN)

Mindset Pharma (MSET) announced a licensing agreement allowing Cybin (CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds.